OVERVIEW

Individualizing Diabetes Care: The Impact of CV Risk on Therapeutic Strategy is organized by National Association for Continuing Education (NACE).

Start Date: 12/15/2019
Expiration Date: 12/14/2020

Accreditation:
The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 Contact Hour of continuing education which includes 0.75 pharmacology hours.

Course Description:
Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality in the United States, and its prevalence has been increasing. An estimated 23.4 million American adults have diagnosed diabetes, 7.6 million have undiagnosed disease, and 81.6 million have prediabetes. Long-standing T2DM is associated with cardiovascular complications, and increased morbidity and mortality outcomes. Therefore, the optimal management of T2DM should not only aim at achieving glycemic control but should also include the management of cardiovascular risk factors and associated cardiovascular disease (CVD).

This activity will explore the pathophysiology of ASCVD and CHF, the mechanism of action of the SGLT-2 class to improve CV outcomes and prevent CKD, and strategies to integrate the evolving clinical data into the management of patients with diabetes.

Learning Objectives:
After completing this program participants should be able to:
• Review the pathophysiology of atherosclerotic cardiovascular disease (ASCVD) and congestive heart failure (CHF) in type 2 diabetes mellitus (T2DM)
• Recognize how the mechanism of action of the sodium glucose co-transporter-2 (SGLT-2) inhibitor class can potentially have a beneficial impact on cardio-renal disease
• Discuss Cardiovascular Outcomes Trials (CVOTs) to date in T2DM and the impact of the SGLT-2 inhibitor class on improving cardiovascular outcomes and preventing progression of chronic kidney disease (CKD)
• Incorporate evolving clinical data into the management of diabetes in patients with, or at high risk for, cardiovascular disease (CVD)